Total submissions: 9
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000127516 | SCV000171093 | benign | not specified | 2013-04-04 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
| Eurofins Ntd Llc |
RCV000710184 | SCV000332199 | uncertain significance | not provided | 2017-08-01 | criteria provided, single submitter | clinical testing | |
| Illumina Laboratory Services, |
RCV000263177 | SCV000394284 | uncertain significance | POLG-Related Spectrum Disorders | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
| Labcorp Genetics |
RCV000457002 | SCV000556236 | likely benign | Progressive sclerosing poliodystrophy | 2025-01-14 | criteria provided, single submitter | clinical testing | |
| Athena Diagnostics | RCV000710184 | SCV000614709 | likely benign | not provided | 2019-06-30 | criteria provided, single submitter | clinical testing | |
| Wong Mito Lab, |
RCV000457002 | SCV000887075 | benign | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.2028G>A (NP_002684.1:p.Ala676=) [GRCH38: NC_000015.10:g.89324149C>T] variant in POLG gene is interpretated to be a Benign based on ACMG guidelines (PMID: 25741868). This variant meets the following evidence codes reported in the ACMG-guideline. BS1:The minor allele frequency of this allele is high for Mitochondrial DNA depletion syndrome 4A (Alpers type). BS2:Observation of the variant in controls is inconsistent with penetrance of Mitochondrial DNA depletion syndrome 4A (Alpers type). BP4:Computational evidence/predictors indicate no impact on the POLG structure, function, or protein-protein interaction. Based on the evidence criteria codes applied, the variant is suggested to be Benign. |
| Ce |
RCV000710184 | SCV001149567 | likely benign | not provided | 2025-02-01 | criteria provided, single submitter | clinical testing | POLG: BP4, BP7 |
| Genome Diagnostics Laboratory, |
RCV001847749 | SCV002105561 | uncertain significance | Hereditary spastic paraplegia | 2018-02-01 | criteria provided, single submitter | clinical testing | |
| Ambry Genetics | RCV002415616 | SCV002718007 | likely benign | Inborn genetic diseases | 2017-12-18 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |